Novo (NOVOB80) – tečaj delnic in novice

Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. Wikipedia

Vizitka: Novo

Generalni direktorMaziar Mike Doustdar

Št. zaposlenih66,7 tis.

Ustanovljeno1923

SedežBagsværd, Capital Region of Denmark, Danska

Sektor-

Spletno mestonovonordisk.com

Vse vrednosti v valuti DKK	sep. 2025	dec. 2025	mar. 2026	jun. 2026
Prihodek	74,98 mrd.	79,14 mrd.	96,82 mrd.	78,49 mrd.
Strošek prodanega blaga	14,47 mrd.	14,17 mrd.	13,60 mrd.	17,10 mrd.
Stroški materiala in storitev	14,47 mrd.	14,17 mrd.	13,60 mrd.	17,10 mrd.
Stroški raziskav in razvoja	11,49 mrd.	12,67 mrd.	10,28 mrd.	11,46 mrd.
Skupni stroški raziskav in razvoja	-	-	-	-
Stroški prodaje, splošni in administrativni stroški	15,76 mrd.	17,14 mrd.	13,22 mrd.	16,31 mrd.
Operativni strošek	27,25 mrd.	29,73 mrd.	23,61 mrd.	28,00 mrd.
Skupni operativni stroški	41,72 mrd.	43,90 mrd.	37,20 mrd.	45,10 mrd.
Prihodek iz poslovanja	33,25 mrd.	35,24 mrd.	59,62 mrd.	33,39 mrd.
Drug prihodek, ki ne izhaja iz poslovanja	1,53 mrd.	−241,00 mio.	-	-
Zaslužek pred obdavčitvijo z vključenimi izrednimi postavkami	25,52 mrd.	34,18 mrd.	62,17 mrd.	26,88 mrd.
Zaslužek pred obdavčitvijo brez izrednih postavk	35,09 mrd.	37,62 mrd.	62,17 mrd.	33,20 mrd.
Odhodek iz obdavčitve dobička	5,51 mrd.	7,29 mrd.	13,62 mrd.	5,89 mrd.
Dejanska davčna stopnja	21,60 %	21,34 %	21,90 %	21,90 %
Drugi operativni stroški	-	−81,00 mio.	106,00 mio.	234,00 mio.
Čisti prihodek	20,01 mrd.	26,89 mrd.	48,56 mrd.	20,99 mrd.
Neto stopnja dobička	26,68 %	33,98 %	50,15 %	26,74 %
Čisti dobiček na delnico	4,50	6,04	6,63	6,18
Prihodki iz obresti in naložb	307,00 mio.	4,41 mrd.	-	1,31 mrd.
Obrestni odhodki	-	−4,97 mrd.	-	−1,50 mrd.
Neto obrestni odhodki	307,00 mio.	−560,00 mio.	-	−186,00 mio.
Stroški amortizacije	-	-	-	-
EBITDA	36,49 mrd.	36,66 mrd.	63,13 mrd.	36,99 mrd.
Dobiček ali izguba pri prodaji sredstev	-	-	-	-

Vprašajte kar koli